Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases

[1]  R. Azevedo,et al.  T Cells Induce Pre-Metastatic Osteolytic Disease and Help Bone Metastases Establishment in a Mouse Model of Metastatic Breast Cancer , 2013, PloS one.

[2]  A. Schetter,et al.  Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma , 2013, International journal of cancer.

[3]  H. Azim,et al.  Targeting RANKL in breast cancer: bone metastasis and beyond , 2013, Expert review of anticancer therapy.

[4]  J. Bernhagen,et al.  The vascular biology of macrophage migration inhibitory factor (MIF) , 2013, Thrombosis and Haemostasis.

[5]  D. Prockop,et al.  Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity. , 2012, Cell stem cell.

[6]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[7]  V. L. La Russa,et al.  Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis , 2012, Clinical & Experimental Metastasis.

[8]  P. Kanellou,et al.  Role of platelet‐derived growth factor‐AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma , 2012, Hematological oncology.

[9]  J. Massagué,et al.  Molecular Pathways Molecular Pathways : VCAM-1 as a Potential Therapeutic Target in Metastasis , 2012 .

[10]  G. van der Pluijm,et al.  Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma , 2012, Molecular Cancer Research.

[11]  L. Martinez,et al.  Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines , 2012, Cancer Cell International.

[12]  F. Climent,et al.  RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. , 2012, Cancer research.

[13]  J. Chirgwin.  The stem cell niche as a pharmaceutical target for prevention of skeletal metastases. , 2012, Anti-cancer agents in medicinal chemistry.

[14]  W. Kraemer,et al.  Changes in Cytokines of the Bone Microenvironment during Breast Cancer Metastasis , 2012, International journal of breast cancer.

[15]  J. Massagué,et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.

[16]  T. Guise,et al.  Therapeutic strategies to target TGF-β in the treatment of bone metastases. , 2011, Current pharmaceutical biotechnology.

[17]  Y. Tao,et al.  Platelet-Derived Growth Factor Regulates Breast Cancer Progression via β-Catenin Expression , 2011, Pathobiology.

[18]  Dong-mei Li,et al.  Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets , 2011, Breast Cancer Research and Treatment.

[19]  D. Lyden,et al.  The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.

[20]  V. Ponomarev,et al.  Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  C. Porta,et al.  Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases , 2011, Journal of cellular physiology.

[22]  M. Hristov,et al.  Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment , 2010, Journal of cellular and molecular medicine.

[23]  G. Pluijm.  Epithelial plasticity, cancer stem cells and bone metastasis formation. , 2011 .

[24]  G. van der Pluijm.  Epithelial plasticity, cancer stem cells and bone metastasis formation. , 2011, Bone.

[25]  J. Schneider,et al.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. , 2011, Bone.

[26]  T. Meshel,et al.  Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition , 2011, BMC Cancer.

[27]  Yu-Chi Chen,et al.  Breast cancer metastasis to the bone: mechanisms of bone loss , 2010, Breast Cancer Research.

[28]  D. Kaplan,et al.  Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. , 2010, Cancer research.

[29]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Waltham,et al.  Epithelial-to-Mesenchymal Transitions and Circulating Tumor Cells , 2010, Journal of Mammary Gland Biology and Neoplasia.

[31]  V. L. La Russa,et al.  Mesenchymal stromal cells, colony-forming unit fibroblasts, from bone marrow of untreated advanced breast and lung cancer patients suppress fibroblast colony formation from healthy marrow. , 2010, Stem cells and development.

[32]  V. Bloemen,et al.  Intercellular adhesion molecule-1 clusters during osteoclastogenesis. , 2009, Biochemical and biophysical research communications.

[33]  E. Dahl,et al.  Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer , 2009, BMC Cancer.

[34]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[35]  E. Dirice,et al.  High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients , 2009, Pancreas.

[36]  C. Lawson,et al.  ICAM-1 signaling in endothelial cells , 2009, Pharmacological reports : PR.

[37]  F. Entschladen,et al.  Cell Communication and Signaling BioMed Central Review Extravasation of leukocytes in comparison to tumor cells , 2008 .

[38]  Baolin Zhang,et al.  TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5 , 2008, Molecular Cancer Research.

[39]  G. Lorusso,et al.  The tumor microenvironment and its contribution to tumor evolution toward metastasis , 2008, Histochemistry and Cell Biology.

[40]  Q. Shi,et al.  An active role for soluble and membrane intercellular adhesion molecule-1 in osteoclast activity in vitro , 2008, Journal of Bone and Mineral Metabolism.

[41]  P. Heikkilä,et al.  Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer. , 2008, Cancer letters.

[42]  K. Packman,et al.  Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow , 2008, PloS one.

[43]  L. Xing,et al.  Functions of RANKL/RANK/OPG in bone modeling and remodeling. , 2008, Archives of biochemistry and biophysics.

[44]  Bo Wang,et al.  Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. , 2008, Cancer letters.

[45]  T. Okada,et al.  A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1 , 2008, Clinical & Experimental Metastasis.

[46]  T. Rachner,et al.  Fatal attraction: why breast cancer cells home to bone , 2008, Breast Cancer Research.

[47]  L. Suva,et al.  Osteoprotegrin and the bone homing and colonization potential of breast cancer cells , 2008, Journal of cellular biochemistry.

[48]  P. Dijke,et al.  TGF-β and BMP7 interactions in tumour progression and bone metastasis , 2007, Clinical & Experimental Metastasis.

[49]  F. Entschladen,et al.  Surface molecules regulating rolling and adhesion to endothelium of neutrophil granulocytes and MDA-MB-468 breast carcinoma cells and their interaction , 2007, Cellular and Molecular Life Sciences.

[50]  E. Dahl,et al.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity , 2007, Oncogene.

[51]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[52]  P. Lin,et al.  Endothelial cell adhesion molecules and cancer progression. , 2007, Current medicinal chemistry.

[53]  P. ten Dijke,et al.  TGF-beta and BMP7 interactions in tumour progression and bone metastasis. , 2007, Clinical & experimental metastasis.

[54]  Kenneth L. van Golen,et al.  Stepping out of the flow: capillary extravasation in cancer metastasis , 2007, Clinical & Experimental Metastasis.

[55]  Jianhua Wang,et al.  The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis , 2007, Cancer and Metastasis Reviews.

[56]  H. Tohyama,et al.  Transgenic Mice Overexpressing Macrophage Migration Inhibitory Factor (MIF) Exhibit High‐Turnover Osteoporosis , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[57]  I. Holen,et al.  Osteoprotegerin (OPG)—a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis? , 2006, International journal of cancer.

[58]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[59]  S. Cross,et al.  Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables , 2006, Journal of Clinical Pathology.

[60]  S. Cross,et al.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours , 2006, Journal of Clinical Pathology.

[61]  M. Kriss,et al.  Human Microvascular Endothelial Cell Activation by IL‐1 and TNF‐α Stimulates the Adhesion and Transendothelial Migration of Circulating Human CD14+ Monocytes That Develop With RANKL Into Functional Osteoclasts , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  H. Silva,et al.  Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. , 2006, Neoplasma.

[63]  Ivo Que,et al.  Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. , 2005, Cancer research.

[64]  John H. White,et al.  Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line. , 2005, Biomedical research.

[65]  M. Kandefer-Szerszeń,et al.  Role of reactive oxygen species (ROS), metalloproteinase‐2 (MMP‐2) and interleukin‐6 (IL‐6) in direct interactions between tumour cell spheroids and endothelial cell monolayer , 2005, Cell biology international.

[66]  Stefan Kammerer,et al.  Role of ICAM1 in invasion of human breast cancer cells. , 2005, Carcinogenesis.

[67]  D. Nam,et al.  Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  D. Allred,et al.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study , 2004, Modern Pathology.

[69]  L. Suva,et al.  Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[70]  I. Holen,et al.  Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis , 2004, Breast Cancer Research and Treatment.

[71]  T. Yoneda,et al.  Osteolytic bone metastasis in breast cancer , 2004, Breast Cancer Research and Treatment.

[72]  R. Dirks,et al.  Signals controlling the expression of PDGF , 2004, Molecular Biology Reports.

[73]  G. Roodman.  Role of stromal-derived cytokines and growth factors in bone metastasis. , 2003 .

[74]  C. Malone,et al.  Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. , 2002, European journal of cancer.

[75]  C. Fraga,et al.  Higher oxidation and lower antioxidant levels in peripheral blood plasma and bone marrow plasma from advanced cancer patients , 2002, Cancer.

[76]  N. Funata,et al.  Expression of Macrophage Migration Inhibitory Factor in Human Breast Cancer: Association with Nodal Spread , 2002, Japanese journal of cancer research : Gann.

[77]  I. Clemmensen,et al.  Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL‐8, PDGF and angiostatin in relation to vascular density of xenografts in vivo , 2000, International journal of cancer.

[78]  H. Kleinman,et al.  Angiogenic activity of human soluble intercellular adhesion molecule-1. , 1999, Cancer research.

[79]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[80]  I. Adachi,et al.  Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. , 1999, International journal of oncology.

[81]  Zhongmin Zhang,et al.  Platelet-Derived Growth Factor (PDGF)-BB Stimulates Osteoclastic Bone Resorption Directly: The Role of Receptor β☆☆☆ , 1998 .

[82]  D. Jin,et al.  Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor beta. , 1998, Biochemical and biophysical research communications.

[83]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[84]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .